Extended follow-up with the Bruton’s tyrosine kinase inhibitor ibrutinib in previously treated Waldenström’s macroglobulinemia.

A letter to the editor is presented regarding the extended follow-up with ibrutinib, an inhibitor of Bruton's tyrosine kinase, in previously treated patients with the non-Hodgkin lymphoma Waldenström's macroglobulinemia.